Imagine a medical breakthrough that could change the lives of patients with a devastating kidney condition. But what if the key lies in targeting a specific protein channel?
A recent study presented at the American Society of Nephrology Kidney Week 2025 reveals promising results for patients with focal segmental glomerulosclerosis (FSGS), a condition that leads to kidney failure in nearly half of affected individuals within a decade. The culprit? A protein channel called TRPC6, which, when overactive, contributes to the loss of specialized kidney cells called podocytes, resulting in worsening kidney function.
Here's where it gets intriguing: Researchers identified that inherited mutations causing TRPC6 to be overactive lead to genetic FSGS. This discovery shines a spotlight on TRPC6 as a potential therapeutic target.
The study, led by Dr. Nicholas Cross, focused on BI 764198, an oral medication designed to selectively inhibit TRPC6. In this phase 2 trial, patients with primary or genetic FSGS were randomly assigned to receive different doses of BI 764198 or a placebo for 12 weeks. The primary goal was to measure the drug's effectiveness in reducing proteinuria, a key indicator of kidney health, by at least 25%.
And the results are encouraging: At the end of the trial, 44% of patients on the 20 mg dose, 14% on the 40 mg dose, and 43% on the 80 mg dose showed significant proteinuria improvements, far surpassing the 7% response rate in the placebo group. Notably, all patients with TRPC6 mutations who received BI 764198 experienced a proteinuria response, compared to none in the placebo group.
BI 764198 was well-tolerated, with no significant differences in adverse events across treatment groups. The study authors concluded that this podocyte-targeted therapy demonstrated efficacy in FSGS patients, marking a potential new treatment approach.
This research opens up exciting possibilities, but it also raises questions. Could targeting TRPC6 be the long-awaited solution for FSGS patients? What are your thoughts on this promising yet controversial approach? The medical community eagerly awaits further developments.
